Gilead Sciences

EFPIA: http://www.efpia.eu

Europabio http://www.europabio.org

EUCOPE http://www.eucope.org

AMCHAM EU: http://www.amchameu.eu

BRITCHAM EU: https://www.britcham.eu/

None declared

Promotes their own interests or the collective interests of their members

Jan 2023 - Dec 2023

1,000,000€ - 1,249,999€

None declared

1,000,000€ - 1,249,999€

This estimate includes costs attributable to covered activities, including consulting fees, meeting costs and the pro-rata salary and travel costs of Gilead Sciences' staff involved in representation to the European institutions, based on the proportion of employee time spent on these activities. The two dedicated 100% FTEs started in September 2022 and are calculated pro-rata for the financial year of 2022.

none

N/A

Support to and participation in multi-stakeholder initiatives advocating for policy initiatives towards elimination of hepatitis C, promoting improved long term health outcomes for people living with HIV and exploring policy options to improve access to cancer treatments and ATMPs across Europe;

Sponsorship of a journalistic investigation on HIV independently carried out by POLITICO Europe.

None declared

12 meetings found. Download meetings

The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.

• Date	19 Jan 2024	Location	Videoconference
  Subject	Meeting with Spanish Women’s Coalition on Triple Negative Breast Cancer on Europe’s Beating Cancer Plan and EU policies on cancer
  Cabinet	Cabinet of Commissioner Stella Kyriakides
  Attending	Tove Ernst (Cabinet member) Stella Kyriakides (Commissioner)

• Date	22 Mar 2023	Location	Brussels
  Subject	Discussed Gilead’s manufacturing operations in Ireland and globally. Gilead outlined their concerns with the soon to be published EU Pharmaceutical strategy, with particular emphasis on unmet medical needs, regulatory data protection and innovation
  Cabinet	Cabinet of Commissioner Mairead Mcguinness
  Portfolio	Financial services, financial stability and Capital Markets Union
  Attending	Patricia Reilly (Cabinet member)

• Date	11 Jun 2021	Location	Brussels, virtual meeting
  Subject	Exchange of views on joint procurement and scientific assessment of Remdesivir
  Cabinet	Cabinet of Commissioner Stella Kyriakides
  Portfolio	Health
  Attending	Stella Kyriakides (Commissioner)

• Date	07 Dec 2020	Location	virtual meeting
  Subject	Exchange of views, update on Remdesivir
  Cabinet	Cabinet of Commissioner Stella Kyriakides
  Portfolio	Health
  Attending	Stella Kyriakides (Commissioner)

• Date	16 Oct 2020	Location	Brussels - virtual meeting
  Subject	Exchange of views - update on Remdesivir
  Cabinet	Cabinet of Commissioner Stella Kyriakides
  Portfolio	Health
  Attending	Stella Kyriakides (Commissioner)

• Date	09 Sep 2020	Location	Phone call
  Subject	Discussions/update on Remdesivir
  Cabinet	Cabinet of Commissioner Stella Kyriakides
  Portfolio	Health
  Attending	Stella Kyriakides (Commissioner)

• Date	06 Jul 2020	Location	Brussels
  Subject	VC meeting: Exchange of views on the forthcoming Pharmaceutical Strategy
  Cabinet	Cabinet of Commissioner Stella Kyriakides
  Portfolio	Health
  Attending	Stella Kyriakides (Commissioner)

• Date	02 Jun 2020	Location	Online
  Subject	Update on remdesivir
  Cabinet	Cabinet of Commissioner Stella Kyriakides
  Portfolio	Health
  Attending	Stella Kyriakides (Commissioner)

• Date	06 May 2020	Location	Brussels
  Subject	VC meeting on remdesivir as a developmental medicine, the clinical trial programme, actions taken in respect of making remdesivir available via a compassionate use, Member States' needs and distribution should it receive market authorisation
  Cabinet	Cabinet of Commissioner Stella Kyriakides
  Portfolio	Health
  Attending	Stella Kyriakides (Commissioner)

• Date	07 Apr 2020	Location	Brussels
  Subject	Discussion on medicines (potential treatments, production, clinical trials, access to results)
  Cabinet	Cabinet of Commissioner Stella Kyriakides
  Portfolio	Health
  Attending	Stella Kyriakides (Commissioner)

• Date	25 Sep 2017	Location	Brussels
  Subject	Hepatitis B and C, HIV
  Cabinet	Cabinet of Commissioner Vytenis Andriukaitis
  Portfolio	Health & Food Safety
  Attending	Arunas Vinciunas (Cabinet member)

• Date	19 Jun 2017	Location	Brussels
  Subject	economic situation within the EU, investment climate, deepening of the EMU, social dimension of the European project, financial regulations and markets
  Cabinet	Cabinet of Vice-President Valdis Dombrovskis
  Portfolio	Euro and Social Dialogue, also in charge of Financial Stability, Financial Services and Capital Markets Union
  Attending	Valdis Dombrovskis (Vice-President) Elina Melngaile (Cabinet member)
  Other Lobbyists	Intel Corporation American Chamber of Commerce to the European Union